Wang Y, Li S, Peng Y, Ma W, Wang Y, Li W. Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma. Cancer Innovation 2023. [DOI: 10.1002/cai2.59][Reference Citation Analysis]
2
Lu H, Zhou L, Zhang B, Xie Y, Yang H, Wang Z. Cuproptosis key gene FDX1 is a prognostic biomarker and associated with immune infiltration in glioma. Front Med 2022;9. [DOI: 10.3389/fmed.2022.939776][Reference Citation Analysis]
3
Sun H, Li X, Yang J, Lyu Y, Han P, Zheng J. A Novel Cuprotosis-Related lncRNA Signature Predicts Survival Outcomes in Patients with Glioblastoma. Intelligent Computing Theories and Application 2022. [DOI: 10.1007/978-3-031-13829-4_48][Reference Citation Analysis]